In a special episode of Lung Cancer Considered, host Dr. Stephen Liu discuss the recent FDA approval of pembrolizumab plus platinum and pemetrexed for mesothelioma, based on the phase III KEYNOTE 483 study.

Guest: Dr. Ibiayi Dagogo-Jack is a thoracic oncologist from Massachusetts General Hospital and Assistant Professor at Harvard Medical School

Guest: Dr. Quincy Chu is a thoracic oncologist at the University of Alberta Cross Cancer Institute’s New Drug Development Program and CCTG Investigational New Drug Committee Chair

In a special episode of Lung Cancer Considered, host Dr. Stephen Liu discuss the recent FDA approval of pembrolizumab plus platinum and pemetrexed for mesothelioma, based on the phase III KEYNOTE 483 study. Guest: Dr. Ibiayi Dagogo-Jack is a thoracic oncologist from Massachusetts General Hospital and Assistant Professor at Harvard Medical School Guest: Dr. Quincy Chu is a thoracic oncologist at the University of Alberta Cross Cancer Institute’s New Drug Development Program and CCTG Investigational New Drug Committee Chair

FDA Approval: KEYNOTE 483, Pembrolizumab plus Chemotherapy for Mesothelioma

Dr. Stephen Liu and Dr. Narjust Florez host Lung Cancer Considered, the podcast of The International Association for the Study of Lung Cancer (IASLC). IASLC is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 6,500 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Visit www.iaslc.org for more information.

Lung Cancer considered is funded in part by AstraZeneca, Daiichi Sankyo, Inc., and Takeda

Science

Dr. Stephen Liu and Dr. Narjust Florez host Lung Cancer Considered, the podcast of The International Association for the Study of Lung Cancer (IASLC). IASLC is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 6,500 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Visit www.iaslc.org for more information. Lung Cancer considered is funded in part by AstraZeneca, Daiichi Sankyo, Inc., and Takeda

Share FDA Approval: KEYNOTE 483, Pembrolizumab plus Chemotherapy for Mesothelioma

Sign up to save your podcasts

FDA Approval: KEYNOTE 483, Pembrolizumab plus Chemotherapy for Mesothelioma

FDA Approval: KEYNOTE 483, Pembrolizumab plus Chemotherapy for Mesothelioma

More shows like Lung Cancer Considered

Lung Cancer Update

Marketplace

Planet Money

Freakonomics Radio

The Daily

Up First from NPR

The Readout Loud

Life Kit

The Journal.

Consider This from NPR

Hard Fork

Two Onc Docs

NEJM AI Grand Rounds

The Top Line

The Headlines